


B. Claims

Please amend claims 11, 12, and 17 as follows. The following is a complete listing of the claims in this application and replaces all earlier versions and all earlier listings of the claims.

1. (Previously Presented) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen.

2. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

- 2-{[(2,4-dichlorophenoxy)acetyl]amino} benzoic acid;
- 2-{[(2,5-dimethylphenoxy)acetyl]amino} benzoic acid;
- 2-{[(2-ethoxy-5-Z-(2-propenyl)phenoxy)acetyl]amino} benzoic acid;
- 2-{[(2-bromo-5-fluorophenoxy)acetyl]amino} benzoic acid;
- 2-{[(2-methyl-5-nitrophenoxy)acetyl]amino} benzoic acid;
- 2-{[(2-fluoro-5-methylphenoxy)acetyl]amino} benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
- 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
- 2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
- 2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
- 2-{[(3-chlorophenoxy)acetyl]amino} benzoic acid;
- 2-{[(3-chlorophenoxy)acetyl]amino}-5-fluorobenzoic acid;
- 2-{[(3-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[(3-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[(2S)-2-(4-chlorophenoxy)propanoyl]amino} benzoic acid;
- 2-{[(2,3-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
2-{{[(2,4-dibromophenoxy)acetyl]amino}benzoic acid;
2-{{[(2-chlorophenoxy)acetyl]amino}benzoic acid;
2-{{[N-(3-bromophenyl)glycyl]amino}benzoic acid;
2-{{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino}benzoic

acid;

2-{{[(4-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;
2-{{[(5-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;
2-{{[(3,4-difluorophenoxy)acetyl]amino}benzoic acid;
2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;
2-{{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;
2-{{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;
2-{{[(2-cyanophenoxy)acetyl]amino}benzoic acid;
5-hydroxy-2-{{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
2-{{[(2-chloro-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;
2-({[(4-chloro-3-(trifluoromethyl)phenoxy]acetyl}amino}benzoic

acid;

2-{{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}benzoic

acid;

2-{{[(2-ethyl-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;
2-({{[(3,4-dichlorophenyl)sulfanyl]acetyl}amino}benzoic acid;
2-({{[(4-chlorophenyl)sulfanyl]acetyl}amino}benzoic acid;

2-{{(2-bromo-4,5-difluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3-(trifluoromethyl)phenoxy)acetyl}amino}benzoic acid;

2-{{(2-bromo-4-chloro-5-methylphenoxy)acetyl}amino}-5-

hydroxybenzoic acid;

2-{{(2,4,5-trifluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-dichlorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{((3,5-trichlorophenyl)thio)acetyl}amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid};

2-{{(3,5-difluorophenoxy)acetyl}amino}benzoic acid;

2-{{(3,5-difluorophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-bromophenoxy)acetyl}amino}-5-hydroxybenzoic acid;

2-{{(2-chloro-6-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(4-chloro-3-ethylphenoxy)acetyl}amino}benzoic acid;

2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid};

5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid};

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}benzoic acid;

2-{{(3-chloro-4-methylphenoxy)acetyl}amino}-5-hydroxybenzoic

acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{(2-chloro-5-fluorophenoxy)acetyl}amino}-5-hydroxybenzoic

acid;

2-{{(3-chloro-4-fluorophenoxy)acetyl}amino}benzoic acid;

2-{{[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{{[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;

2-{{[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;

2-{{[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{{[N-(2-fluoro-4-methylphenyl)glycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(2,5-dichlorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-

hydroxybenzoic acid;

- 2-{[N-(3-chloro-4-fluorophenyl)glycyl]amino} benzoic acid;
- 2-{[(3,4,-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[(2-bromo-4-methylphenoxy)acetyl]amino} benzoic acid;
- 2-{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
- 2-{[2-(2-chloro-phenoxy)acetyl]amino} benzoic acid;
- 2-[{(4-bromophenyl)methyl} {2-isopropyl-5-

methylphenoxyacetyl]amino} benzoic acid;

- 2-{[(4-cyclohexylphenoxy)acetyl]amino} benzoic acid; and

pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 1 wherein the compound is selected from the group consisting of

- 2-{[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;
- 2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
- 2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

and pharmaceutically acceptable salts thereof.

4. (Original) The method of claim 1 wherein the compound is selected from the group consisting of


- 5-hydroxy-2--{[(2,4,5-trichlorophenoxy)acetyl]amino} benzoic acid;

2-{{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

5. (Original) The method of claim 1 wherein the mammal is human.
6. (Original) The method of claim 5 wherein the composition is administered orally to said human.
7. (Original) The method of claim 6 wherein the compound is administered orally at a dose range of about 0.01 to 100 mg/kg from 1 to 6 times a day.
8. (Original) The method of claim 7 wherein the compound is administered orally at a dose range of about 0.1 to 10 mg/kg from 1 to 6 times a day.
9. (Original) The method of claim 8 wherein the compound is administered from 1 to 4 times a day.
10. (Original) The method of claim 5 wherein the composition is administered subcutaneously to said human.

11. (Currently Amended) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

W is CO₂H or 5- tetrazolyl;

Z is hydrogen or mono-methyl and

G is either OH, F, or hydrogen;

and a pharmaceutically acceptable carrier,

with the proviso that when X is NH, G is OH.

12. (Currently Amended) The composition of claim 11 wherein the compound is selected from the group consisting of

2-{{(2,4-dichlorophenoxy)acetyl}amino}benzoic acid;

2-{{(2,5-dimethylphenoxy)acetyl}amino}benzoic acid;

2-[[2-ethoxy-5-Z-(2-propenyl)phenoxy]acetyl]amino} benzoic acid;
 2-[[2-bromo-5-fluorophenoxy]acetyl]amino} benzoic acid;
 2-[[2-methyl-5-nitrophenoxy]acetyl]amino} benzoic acid;
 2-[[2-fluoro-5-methylphenoxy]acetyl]amino} benzoic acid;
 2-[2-(4-Bromo-phenoxy)-acetylamino]-benzoic acid;
 2-[2-(3-Bromo-phenoxy)-acetylamino]-benzoic acid;
 2-[2-(2-Bromo-phenoxy)-acetylamino]-benzoic acid;
 2-[2-(4-Bromo-phenoxy)-propionylamino]-benzoic acid;
 2-[2-(4-Bromo-phenylsulfanyl)-acetylamino]-benzoic acid;
 2-[2-(4-Chloro-phenoxy)-acetylamino]-benzoic acid;
 2-[2-(4-Fluoro-phenoxy)-acetylamino]-benzoic acid;
 2-[[3-chlorophenoxy]acetyl]amino} benzoic acid;
 2-[[3-chlorophenoxy]acetyl]amino}-5-fluorobenzoic acid;
 2-[[3-chlorophenoxy]acetyl]amino}-5-hydroxybenzoic acid;
 2-[[3,4-dimethylphenoxy]acetyl]amino}-5-hydroxybenzoic acid;
 2-[[3-bromophenoxy]acetyl]amino}-5-hydroxybenzoic acid;
 2-[[2S)-2-(4-chlorophenoxy)propanoyl]amino} benzoic acid;
 2-[[2,3-dichlorophenoxy]acetyl]amino}-5-hydroxybenzoic acid;
 2-[[2,4,5-trichlorophenoxy]acetyl]amino} benzoic acid;
 2-[[2,4-dibromophenoxy]acetyl]amino} benzoic acid;
 2-[[2-chlorophenoxy]acetyl]amino} benzoic acid;
 2-[[N-(3-bromophenyl)glycyl]amino} benzoic acid;

2-{{[N-(4-bromo-3-chlorophenyl)-N-methylglycyl]amino}benzoic
acid;

2-{{[(4-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{{[(5-chloro-2-methylphenoxy)acetyl]amino}benzoic acid;

2-{{[(3,4-difluorophenoxy)acetyl]amino}benzoic acid;

2-(4-chlorophenoxy)-N-[2-(1H-tetrazol-5-yl)phenyl]acetamide;

2-{{[N-(3,4-dibromophenyl)-N-methylglycyl]amino}benzoic acid;

2-{{[N-(2,5-dibromophenyl)glycyl]amino}benzoic acid;

2-{{[(2-cyanophenoxy)acetyl]amino}benzoic acid;

5-hydroxy-2-{{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;

2-{{[(2-chloro-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-{{[[4-chloro-3-(trifluoromethyl)phenoxy]acetyl]amino}benzoic
acid;

2-{{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}benzoic
acid;

2-{{[(2-ethyl-4,5-dimethylphenoxy)acetyl]amino}benzoic acid;

2-{{[(3,4-dichlorophenyl)sulfanyl]acetyl]amino}benzoic acid;

2-{{[(4-chlorophenyl)sulfanyl]acetyl]amino}benzoic acid;

2-{{[(2-bromo-4,5-difluorophenoxy)acetyl]amino}benzoic acid;

2-{{[3-(trifluoromethyl)phenoxy]acetyl]amino}benzoic acid;

2-{{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-
hydroxybenzoic acid;

2-{{(2,4,5-trifluorophenoxy)acetyl}amino} benzoic acid;
 2-{{[(3,5-dichlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{{[(2,4,5-trichlorophenyl)thio]acetyl}amino}benzoic acid;
 2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}benzoic acid;
 2-{{[(3,5-difluorophenoxy)acetyl]amino}benzoic acid;
 2-{{[(3,5-difluorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{{[(2-bromophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{{[(2-chloro-6-methylphenoxy)acetyl]amino}benzoic acid;
 2-{{[(4-chloro-3-ethylphenoxy)acetyl]amino}benzoic acid;
 2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;
 5-hydroxy-2-{{[N-(2,4,5-trichlorophenyl)glycyl]amino}benzoic acid;
 2-{{[(3-chloro-4-methylphenoxy)acetyl]amino}benzoic acid;
 2-{{[(3-chloro-4-methylphenoxy)acetyl]amino}-5-hydroxybenzoic
 acid;
 2-{{[(2-chloro-5-fluorophenoxy)acetyl]amino}benzoic acid;
 2-{{[(2-chloro-5-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
 acid;
 2-{{[(3-chloro-4-fluorophenoxy)acetyl]amino}benzoic acid;
 2-{{[(3-chloro-4-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
 acid;
 2-{{[(4-chloro-3-fluorophenoxy)acetyl]amino}benzoic acid;
 2-{{[N-(3,4-difluorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(4-chloro-2-fluorophenyl)glycyl]amino}benzoic acid;

2-{{[(4-chloro-3-fluorophenoxy)acetyl]amino}-5-hydroxybenzoic
acid;

2-{{[N-(2-fluoro-4-methylphenyl)glycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(2,5-dichlorophenyl)glycyl]amino}benzoic acid;

2-{{[N-(2,5-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-ethylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}benzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-propylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(2,5-dichlorophenyl)-N-methylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-
hydroxybenzoic acid;

2-{{[N-(3-chloro-4-fluorophenyl)glycyl]amino}benzoic acid;

2-{{[(3,4-dimethylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{{[(2-chlorophenoxy)acetyl]amino}-5-hydroxybenzoic acid;

2-{[(2-bromo-4-methylphenoxy)acetyl]amino}benzoic acid;
 2-{[(4-nitrophenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{[2-(2-chloro-phenoxy)acetyl]amino}benzoic acid;
 2-[{(4-bromophenyl)methyl}{2-isopropyl-5-methylphenoxyacetyl]amino}benzoic acid;
 2-{[(4-cyclohexylphenoxy)acetyl]amino}benzoic acid, and
 pharmaceutically acceptable salts thereof.


13. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
 2-{[N-(2,5-dibromophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 2-{[N-(3,4-dichlorophenyl)glycyl]amino}-5-hydroxybenzoic acid;
 and pharmaceutically acceptable salts thereof.

14. (Original) The composition of claim 11 wherein the compound is selected from the group consisting of

5-hydroxy-2-{[(2,4,5-trichlorophenoxy)acetyl]amino}benzoic acid;
 2-{[(2-bromo-4-chloro-5-methylphenoxy)acetyl]amino}-5-hydroxybenzoic acid;
 2-{[N-(3,4-dichlorophenyl)-N-methylglycyl]amino}-5-hydroxybenzoic acid; and pharmaceutically acceptable salts thereof.

15. (Original) A method of treating hepatitis C in a mammal having symptoms of hepatitis C comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C₂-C₄ alkenyl, cyano, and trifluoromethyl;

X is O, S, NH, or NR where R is a C₁-C₄ alkyl group;

Y is CO₂H or CO₂CH₃;

Z is hydrogen or mono-methyl;

G₁ is OH, F, methoxy or hydrogen; and

G₂ is either OH, Cl, methoxy or hydrogen.


16. (Original) The method of claim 15 wherein the compound is selected from the group consisting of

2-[(4-chlorophenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-methoxyphenoxy)acetylamino]-benzoic acid methyl ester;

2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
 2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;
 2-[[3,4,-dimethylphenoxy)acetyl]amino}-4-hydroxybenzoic acid;
 2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
 2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and
 pharmaceutically acceptable salts thereof.

17. (Currently Amended) A pharmaceutical composition for the treatment of hepatitis comprising a compound having the structure



and pharmaceutically acceptable salts thereof, wherein:

R_1 , R_2 , R_3 , R_4 and R_5 are independently selected from the group consisting of hydrogen, halogen, methyl, ethyl, methoxy, nitro, C_2 - C_4 alkenyl, cyano, and trifluoromethyl;

X is O, S, NH_2 - or NR where R is a C_1 - C_4 alkyl group;

Y is CO_2H ;

Z is hydrogen or mono-methyl;

G_1 is OH, F, methoxy or hydrogen; and

G₂ is either OH, Cl, methoxy or hydrogen;
and a pharmaceutically acceptable carrier.

18. (Previously Presented) The pharmaceutical composition of claim 17 wherein the compound is selected from the group consisting of
- 2-[(4-cyclohexylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
 - 2-[(2-phenoxy)propionylamino]-4-hydroxybenzoic acid;
 - 2-[[[(3,4,-dimethylphenoxy)acetyl]amino]-4-hydroxybenzoic acid;
 - 2-[(3-methylphenoxy)acetylamino]-4,5-dimethoxybenzoic acid;
 - 2-[(3-methylphenoxy)acetylamino]-4-chlorobenzoic acid; and
- pharmaceutically acceptable salts thereof.